Lv5
958 积分 2024-07-04 加入
Fibroblast growth factor signalling: from development to cancer
3小时前
待确认
Advances and challenges in targeting FGFR signalling in cancer
3小时前
待确认
Discovery of Pemigatinib: A Potent and Selective Fibroblast Growth Factor Receptor (FGFR) Inhibitor
3小时前
待确认
FGFR1-amplified colorectal cancer: a distinct prognostic subtype identified through integrated genomic and immunohistochemical profiling
3小时前
待确认
Discovery of Daraxonrasib (RMC-6236), a Potent and Orally Bioavailable RAS(ON) Multi-selective, Noncovalent Tri-complex Inhibitor for the Treatment of Patients with Multiple RAS-Addicted Cancers
3小时前
已完结
Efficacy and Safety of Olomorasib in Combination with Pembrolizumab in Treatment of Patients with KRAS G12C-Mutant Advanced NSCLC
4小时前
已完结
Divarasib plus cetuximab in KRAS G12C-positive colorectal cancer: a phase 1b trial
4小时前
已完结
Sotorasib plus Panitumumab in Refractory Colorectal Cancer with Mutated KRAS G12C
4小时前
已完结
Atezolizumab in combination with carboplatin plus nab-paclitaxel chemotherapy compared with chemotherapy alone as first-line treatment for metastatic non-squamous non-small-cell lung cancer (IMpower130): a multicentre, randomised, open-label, phase 3 trial
15天前
已完结
皖公网安备34019202002308
